Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
 and Lead Plaintiff Deadline - January 3, 2017 - EconoTimes)
NEW YORK, Nov. 28, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed against Cempra Inc. (“Cempra” or the “Company”) (NASDAQ:CEMP) and certain of its officers. This class action is on behalf of a class consisting of all persons who purchased Cempra between May 1, 2016 and November 1, 2016, both dates inclusive (the "Class Period").
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
On November 2, 2016, the U.S. Food and Drug Administration reported its preliminary review of Cempra’s drug, solithromycin, to treat community-acquired bacterial pneumonia and specified a significant safety signal for hepatotoxicity. Following this news, Cempra stock dropped $9.71 per share or over 58% to $6.95 on November 2, 2016.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that (1) one of Cempra’s lead product candidates, solithromycin, posed significant safety risks for hepatotoxicity; and (2) consequently, Cempra’s public statements were materially false and misleading at all relevant times.
No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm’s site: http://www.bgandg.com/cemp or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Cempra, you have until January 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
